Skip to main navigation

> Main Menu

About Our Company Our History Corporate Values Leadership Team Mission Work Corporate Transparency

Careers

Contact

Investors Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

> Main Menu

About

Our Company Our History Corporate Values Leadership Team Mission Work Corporate Transparency

Careers Contact

Investors

Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

Press Releases

Year

July 19, 2023

Harrow Prices $60 Million Public Offering of Common Stock

July 18, 2023

Harrow Acquires Santen’s Branded Ophthalmic Portfolio

July 18, 2023

Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance

July 18, 2023

Harrow Announces Proposed Public Offering of Common Stock

July 18, 2023

Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq

May 17, 2023

Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023

May 11, 2023

Harrow Announces First Quarter 2023 Financial Results

May 4, 2023

Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

May 2, 2023

Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.

April 27, 2023

Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 29

Address

102 Woodmont Blvd., Suite 610
Nashville, TN 37205

Phone

(615) 733 4730
(615) 733 4737 (Investor Relations)

Social

Copyright © 2023 Harrow, Inc. All rights reserved.

> Footer

Privacy Policy Terms of Use Cookie Notice